Connect public, paid and private patent data with Google Patents Public Datasets

Mittel zur oralen gabe von wirkstoffen

Info

Publication number
DE69411154D1
DE69411154D1 DE1994611154 DE69411154A DE69411154D1 DE 69411154 D1 DE69411154 D1 DE 69411154D1 DE 1994611154 DE1994611154 DE 1994611154 DE 69411154 A DE69411154 A DE 69411154A DE 69411154 D1 DE69411154 D1 DE 69411154D1
Authority
DE
Grant status
Grant
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE1994611154
Other languages
English (en)
Other versions
DE69411154T2 (de )
Inventor
Alfred A Amkraut
Heechung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
DE1994611154 1993-02-22 1994-02-22 Mittel zur oralen gabe von wirkstoffen Expired - Fee Related DE69411154D1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US2048193 true 1993-02-22 1993-02-22
PCT/US1994/001756 WO1994018955A1 (en) 1993-02-22 1994-02-22 Compositions for oral delivery of active agents

Publications (1)

Publication Number Publication Date
DE69411154D1 true DE69411154D1 (de) 1998-07-23

Family

ID=21798853

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1994611154 Expired - Fee Related DE69411154D1 (de) 1993-02-22 1994-02-22 Mittel zur oralen gabe von wirkstoffen
DE1994611154 Expired - Lifetime DE69411154T2 (de) 1993-02-22 1994-02-22 Mittel zur oralen gabe von wirkstoffen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1994611154 Expired - Lifetime DE69411154T2 (de) 1993-02-22 1994-02-22 Mittel zur oralen gabe von wirkstoffen

Country Status (6)

Country Link
US (2) US5620708A (de)
JP (1) JPH08507070A (de)
CA (1) CA2151742C (de)
DE (2) DE69411154D1 (de)
EP (1) EP0684814B1 (de)
WO (1) WO1994018955A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
CA2207961A1 (en) * 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1997036480A1 (en) * 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
JP4203159B2 (ja) * 1997-12-09 2008-12-24 株式会社林原生物化学研究所 神経機能調節剤
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
WO2000054006A3 (en) * 1999-03-08 2001-01-18 Lockheed Corp Single-pass interferometric synthetic aperture radar
WO2001035978A1 (en) * 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
ES2282436T3 (es) * 2001-06-01 2007-10-16 Novartis Ag Administracion oral de hormona paratiroide y calcitonina.
JP2005511761A (ja) * 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
CA2487720A1 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
EP1530482B9 (de) 2002-07-18 2014-04-16 Helix Biopharma Corp. Verwendung von urease zur hemmung des krebszellenwachstums
DK2891666T3 (da) 2002-10-16 2017-10-02 Purdue Pharma Lp Antistoffer, som binder celleassocieret CA 125/O722P, og fremgangsmåder til anvendelse deraf
EP2267027A3 (de) 2002-11-08 2011-07-20 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
WO2004062551A3 (en) 2003-01-10 2004-09-02 Ablynx Nv RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
WO2004041865A3 (en) 2002-11-08 2004-07-15 Ablynx Nv Stabilized single domain antibodies
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
CA2549994A1 (en) * 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
EP1587524A4 (de) * 2003-01-09 2006-07-26 Arizeke Pharmaceuticals Inc Zusammensetzungen und verfahren für die gezielte biologische abgabe von molekularen trägern
EP1610752B1 (de) * 2003-01-31 2013-01-02 Boston Scientific Limited Lokalisierte arzneimittelabgabe unter verwendung von mit arzneimittel beladenen nanokapseln und damit beschichtete implantierbare vorrichtung
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2005100405A3 (en) 2004-04-15 2006-04-13 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
CN101001641A (zh) * 2004-04-29 2007-07-18 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 用于治疗代谢性骨病的包含骨形态发生蛋白的口服制剂
WO2006009825A1 (en) 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006099175A3 (en) * 2005-03-11 2006-12-14 Earl F Albone Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
EP2674440A3 (de) 2005-12-16 2014-03-05 IBC Pharmaceuticals, Inc. Polyvalente bioaktive Anordnungen auf Immunglobulinbasis
DK1888640T3 (da) 2005-05-18 2012-06-18 Ablynx Nv Forbedrede nanobodies mod tumornekrosefaktor-alfa
JP4986997B2 (ja) 2005-05-20 2012-07-25 アブリンクス エン.ヴェー. 凝集媒介障害の治療における改良ナノボディ(商標)
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US8491890B2 (en) 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
WO2010138193A3 (en) 2009-05-27 2011-06-03 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP2523680A4 (de) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
EP2582393A4 (de) 2010-05-26 2014-04-02 Selecta Biosciences Inc Dosisauswahl synthetischer adjuvanz-nanoträger
CA2843960A1 (en) 2011-08-09 2013-02-14 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
KR20140068948A (ko) 2011-08-09 2014-06-09 아테라 바이오테크놀로지스 아베 포스포릴콜린에 대한 신규 항체
EP2768518A4 (de) 2011-10-18 2015-05-27 Aileron Therapeutics Inc Peptidomimetische makrozyklen
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (de) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
CN104812384A (zh) 2012-11-01 2015-07-29 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2900277A4 (de) 2012-12-13 2016-11-02 Immunomedics Inc Dosierungen von immunkonjugaten von antikörpern und sn-38 für verbesserte wirksamkeit und reduzierte toxizität
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) * 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
JPS63264069A (en) * 1987-04-22 1988-10-31 Idemitsu Kosan Co Cell adhesive material
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US5320824A (en) * 1989-10-12 1994-06-14 Mallinckrodt Medical, Inc. Radionuclide labelled particles useful for radiation synovectomy
JPH06504274A (de) * 1991-01-07 1994-05-19
JPH05506040A (de) * 1991-02-14 1993-09-02
ES2108111T3 (es) * 1991-04-02 1997-12-16 Biotech Australia Pty Ltd Sistemas de suministro oral de microparticulas.

Also Published As

Publication number Publication date Type
US5702727A (en) 1997-12-30 grant
EP0684814A1 (de) 1995-12-06 application
DE69411154T2 (de) 1998-10-22 grant
JPH08507070A (ja) 1996-07-30 application
WO1994018955A1 (en) 1994-09-01 application
US5620708A (en) 1997-04-15 grant
CA2151742C (en) 1999-05-25 grant
EP0684814B1 (de) 1998-06-17 grant
CA2151742A1 (en) 1994-09-01 application

Similar Documents

Publication Publication Date Title
DE9407022U1 (de) Konnektor zur kontaminationsfreien Verabreichung von Arzneimitteln (Zytostatika)
DE69315324T2 (de) Mundpflegemittel
DE69315579T2 (de) Vorrichtung zur verabreichung von medikamenten
DE69604316T2 (de) Schlammbehandlungbehälter und Bauverfahren dafür
DE69209083T2 (de) System zur peroralen arzneimittelabgabe
DE29707744U1 (de) 4-Phenylbutyrat enthaltende Mittel zur antineoplastischen Therapie
DE69411579T2 (de) Zusammensetzung und system zur oralen verabreichung an tiere
DE3674237D1 (de) Substituierte azetidinone, diese enthaltende pharmazeutische zusammensetzungen und ihre verwendung zur herstellung von entzuendungshemmenden und antidegenerativen medikamenten.
DK670388D0 (da) Antibiotikumholdigt farmaceutisk praeparat
DE69617659T2 (de) Pharmazeutische zusammensetzungen, welche ausgewählte lanthankarbonathydrate enthalten
DE68917485T2 (de) Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3669064D1 (de) Pharmazeutische zusammensetzungen.
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
FI940115A0 (fi) Nanokapseleita sisältävät farmaseuttiset seokset
DE69318131D1 (de) Fluoridionauslaugbare gläser und zahnzementzusammensetzungen
DE69614855D1 (de) Gemischte lipid-bicarbonat kolloidale partikel zur abgabe von arzneistoffen oder kalorien
DE69229566T2 (de) Zusammensetzung und verfahren zur freisetzung von arzneistoffen
DE69008346T3 (de) Arzneistoffabgabe-zusammensetzungen.
DE69016532T2 (de) Zahnbelag verhindernde Mittel.
FI934387A0 (fi) 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner
FI952825A (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
DE69124721T2 (de) Carbostyrilderivate und diese enthaltende pharmazeutische Zusammensetzungen
DK0767669T3 (da) Nyt farmaceutisk præparat til smertebehandling
DE69827947T2 (de) Rapamycin-formulierungen zur oralen verabreichung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee